MedPath

Aronora, Inc.

Aronora, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2007-01-01
Employees
1
Market Cap
-
Website
http://www.aronorabio.com

Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

Phase 2
Completed
Conditions
End Stage Renal Disease
Thrombosis
Interventions
Drug: AB002 Dose 1
Drug: AB002 Dose 2
Drug: placebo
First Posted Date
2019-05-28
Last Posted Date
2024-03-07
Lead Sponsor
Aronora, Inc.
Target Recruit Count
40
Registration Number
NCT03963895
Locations
🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis

Phase 2
Completed
Conditions
End Stage Renal Disease
Thrombosis
Interventions
Drug: AB023-Dose 2
Drug: placebo
Drug: AB023- Dose 1
First Posted Date
2018-08-02
Last Posted Date
2024-03-07
Lead Sponsor
Aronora, Inc.
Target Recruit Count
27
Registration Number
NCT03612856
Locations
🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects

Phase 1
Completed
Conditions
Thrombosis
Interventions
Drug: E-WE Thrombin- Dose 1
Drug: E-WE Thrombin- Dose 2
Drug: E-WE Thrombin- Dose 3
Drug: E-WE Thrombin- Dose 4
Other: Placebo
First Posted Date
2018-03-05
Last Posted Date
2019-10-29
Lead Sponsor
Aronora, Inc.
Target Recruit Count
21
Registration Number
NCT03453060
Locations
🇺🇸

Celerion, Tempe, Arizona, United States

Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects

Phase 1
Completed
Conditions
Thrombosis
Interventions
Drug: xisomab 3G3- Dose 4
Drug: xisomab 3G3-Dose 2
Other: Placebo
Drug: xisomab 3G3- Dose 1
Drug: xisomab 3G3-Dose 3
First Posted Date
2017-03-31
Last Posted Date
2019-06-05
Lead Sponsor
Aronora, Inc.
Target Recruit Count
21
Registration Number
NCT03097341
Locations
🇺🇸

Celerion, Tempe, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath